Our congress review will be available here - please check back soon.
Our symposium review will be available here - please check back soon.
JAK inhibitors are advancing management options across immune-mediated inflammatory diseases. To review the role in different rheumatic indications, join us for this symposium at the 2021 APLAR annual congress.
This symposium is independently developed by the Cytokine Signalling Forum and sponsored by Lilly.
|Kevin Winthrop (Chair)|
Welcome and Introduction
JAK inhibition in Rheumatoid Arthritis
|Lai Shan Tam|
JAK Inhibitors in SpA
JAK Inhibitors in SLE
JAK Inhibitors and COVID-19
Questions and Answer Session
Summary and Close
Professor of Infectious Diseases, Public Health and Preventive Medicine, and Ophthalmology, Oregon Health and Science University, USA
Professor Kevin Winthrop received his undergraduate degree in biology from Yale University and completed his MD degree at Oregon Health Sciences University in Portland, Oregon, USA. He obtained a masters degree in epidemiology at University California at Berkeley and completed an infectious disease epidemiology fellowship with the US Centers for Disease Control and Prevention (CDC) before serving as a staff member at CDC. He has co-authored more than 100 publications, many detailing epidemiologic and clinical aspects of infections and other adverse events associated with immune-mediated inflammatory diseases, particularly those related to biologic immunosuppressive therapies. Professor Winthrop also serves on the editorial board of Annals of Rheumatic Diseases, as Section Editor of Current Rheumatology Reports, and as an Associate Editor of BMC Infectious Diseases.
Head of the Department of Internal Medicine, Rheumatology and Clinical Immunology. Director of the Rheumatology Research Center, Charité Universitätsmedizin Berlin
Prof. Dr. Alten completed her training in Internal Medicine at the Free University Berlin, followed by training in Rheumatology in Zürich. In 1984, she received board certification in Internal Medicine, in 1985 in Rheumatology, in 1998 in Physical Therapy and Rehabilitation Medicine, and in 2001 in Sports Medicine. In 1990, she was appointed Head of the Department of Internal Medicine, Rheumatology at Schlosspark-Klinik, University Medicine Berlin. Prof. Dr. Alten’s research interests focus on the development and systematic evaluation of biological and immunolomodulatory treatments for rheumatic diseases.
Prof. Dr. Alten is a member of the OMERACT (Outcome Measures in Rheumatology) Steering Committee of the Flare in Rheumatoid Arthritis Group. She has served as board member of the German Medical Association, the Institute for Approval of Drugs for the German Ministry of Health, the “Kaiser-Friedrich-Stiftung” for postgraduate education in Germany and the German Society of Rheumatology.
She has been the lead investigator in clinical trials of novel therapies in rheumatic diseases and has contributed to several investigator-initiated trials. She has published more than 200 original papers, book chapters and reviews.
Professor and Department Head of Medicine & Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong. Honorary Consultant, Hospital Authority
Lai-Shan Tam, MD, is Division Head and a Professor in the Division of Rheumatology within the Department of Medicine and Therapeutics at The Chinese University of Hong Kong (CUHK). She is also an Honorary Consultant at the Hospital Authority and has been serving as the Chairperson of the International Affair Committee of APLAR since 2012.
She was President of the Hong Kong Society of Rheumatology from 2011 to 2014, and Vice President of APLAR from 2014-2016. In addition, Professor Tam was a member of the International Task Force Subcommittee of ACR and the Task Force Subcommittee of ACR and on the EULAR Programme Committee from 2016-2019, and EULAR honorary member (since 2019). She serves as the Associate Editor of International Journal of Rheumatic Disease, and as members of the editorial boards in a number of journals including Rheumatology, Frontiers in Medicine and the Latin American Journal of Psoriasis and Psoriatic Arthritis, and she is also the international advisory board member of the Lancet Rheumatology.
She is the first author or co-author of over 200 articles published in major rheumatology journals. Her research interests include premature atherosclerosis and bone loss in patients with rheumatic diseases.
Professor of Medicine and Head of the School of Clinical Sciences, Monash University, Melbourne, Australia
Eric Morand is Professor of Medicine and Head of the School of Clinical Sciences at Monash University, and Head of Rheumatology at Monash Health, in Melbourne Australia.
He trained at the Royal National Hospital for Rheumatic Diseases, UK, before completing his PhD at Monash University, where he has led rheumatology research since. He is a member and former Board Member of the Australian Rheumatology Association, and an International Fellow of the American College of Rheumatology. He is an advisor on lupus measurement and trials to multiple pharmaceutical companies. He was Principal Investigator of the TULIP-2 trial of anifrolumab.
He Chaired the 2017 International Congress on SLE and is on the editorial advisory boards of Nature Reviews Rheumatology, The Lancet Rheumatology, and Lupus Science and Medicine. Professor Morand’s outputs include over 250 publications and book chapters, which have been cited >12,000 times. He founded the Lupus Clinic at Monash Health, which lead to the formation of the Australian Lupus Registry and Biobank. He founded and Chair’s the Asia Pacific Lupus Collaboration, with over 4,000 patients under longitudinal follow-up. This group developed and prospectively validated the Lupus Low Disease Activity State (LLDAS) measure for treat-to-target studies in SLE, which has since been validated as a potential clinical trial endpoint.
His laboratory research programme focuses on the effects of glucocorticoid-induced proteins in the immune system, with the overarching goal of finding pathways to deliver glucocorticoid-mimicking therapeutic effects without adverse effects. This led to the description of the expression and function of four novel proteins in rheumatic disease tissues and models. Recent work on glucocorticoid-induced leucine zipper (GILZ) lead to the William E Paul Distinguished Innovator Award of the Lupus Research Alliance, New York, in 2015.